Healthcare Providers and Services
Company Overview of American Diabetes Association, Inc.
American Diabetes Association, Inc. is a non profitable healthcare organization. The company provides research based advisory services focusing on diabetes and its treatment. It also conducts programs and publishes findings. American Diabetes Association, Inc. was founded in 1940 and is based in Alexandria, Virginia with an additional office in Maitland, Florida.
1701 North Beauregard Street
Alexandria, VA 22311
Founded in 1940
Key Executives for American Diabetes Association, Inc.
Chief Executive Officer and Director
Executive Vice President and Chief Financial Officer
President of Health Care & Education and Director
President of Medicine & Science and Director
National Director of Federal Government Affairs
Compensation as of Fiscal Year 2016.
American Diabetes Association, Inc. Key Developments
American Diabetes Association Names William T. Cefalu, MD as Chief Scientific & Medical Officer, Effective Form Feb. 20, 2017
Jan 9 17
William T. Cefalu, MD, has been appointed Chief Scientific & Medical Officer (CSMO) of the American Diabetes Association (Association) and will formally begin serving on Feb. 20, 2017. Cefalu, who has more than 30 years of work in diabetes research and care, replaces Robert E. Ratner, MD, who retired on Dec. 31, 2016, after serving as CSMO for nearly five years. While his work with the Association has spanned nearly two decades, since 2004, Cefalu has served as an Associate Editor of Diabetes and Diabetes Care. As CSMO, he will assist in the transition to new editorial leadership for Diabetes Care. Cefalu joins the Association from Louisiana State University's (LSU) Pennington Biomedical Research Center in Baton Rouge, La., where he has been a Professor since 2003. At Pennington Biomedical, he has held the positions of Associate Executive Director and Chief Scientific Officer, and he currently serves as Executive Director and holds the George A. Bray, Jr. Endowed Super Chair in Nutrition.
Mark Fleisher Joins American Diabetes Association Board of Directors
Sep 29 16
Modernizing Medicine, Inc. announced that Mark Fleisher, senior executive vice president and general counsel, joined the American Diabetes Association (ADA) South Florida board of directors. He was installed on July 1, 2016, and his term will last through June 30, 2017. Mark is a member of Modernizing Medicine’s executive team and has over fifteen years of experience providing legal representation to technology companies.
American Diabetes Association and IBM Watson Health Announce Long-Term Collaboration
Jun 12 16
The American Diabetes Association and IBM Watson Health announced a long-term collaboration to bring together the cognitive computing power of Watson and the Association's vast repository of clinical and research data. The organizations aim to build a diabetes advisor for patients and caregivers. The goal of the collaboration is to develop Watson-powered solutions that enable the diabetes community to optimize clinical, research and lifestyle decisions, and address important issues that influence health outcomes, such as social determinants of health. As part of the collaboration, Watson will be trained to understand diabetes data with the goal to identify potential risk factors and create evidence-based, confidence-ranked recommendations for a range of health decisions. Watson will ingest the Association's rich repository of clinical and scientific data, which includes 66 years of data, as well as the Association's aggregated data about self-management, support groups, health/wellness activities and diabetes education. New offerings developed through the collaboration may also draw on data and insights from IBM's Watson Health Cloud and will leverage Watson's capabilities, such as deep Q&A, natural language processing, engagement advisor, similarity analytics, predictive analytics and personality insights. For providers, the team plans to create a cognitive diabetes database to help inform treatment decisions and care management approaches. Healthcare providers could tap into personality insights through Watson to tailor their treatment approaches to the needs of an individual. Additionally, providers could identify and address potential risk factors for their patients by comparing an individual to population-level trends of patients with similar characteristics. For researchers, the Association and IBM Watson Health plan to create a cloud-based data and insights service that enables scientists to apply Watson to the Association's body of clinical and scientific evidence to help them find hidden patterns, potentially identifying the next frontiers for therapeutic discovery. This tool could accelerate significant breakthroughs in some of the most pressing areas of diabetes research. For patients and caregivers, cognitive tools for people living with diabetes or pre-diabetes could be developed to provide tailored information and insights, reflecting individual factors such as demographics, disease stage, treatment regimen and behaviors. For example, the collaboration could lead to the creation of a mobile app that is integrated with Watson Care Manager and may become increasingly personalized as individuals engage with it, effectively getting "smarter" each time it is used.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|